Bioavailability of KBP-5074 Tablet vs Capsule Formulations
Status:
Unknown status
Trial end date:
2017-12-19
Target enrollment:
Participant gender:
Summary
This is an open-label, partial crossover, single-dose study to evaluate the pharmacokinetics
(PK), dose proportionality, and safety/tolerability of tablet versus capsule formulations of
KBP-5074 in healthy subjects. The study is designed to evaluate the PK of a new tablet
formulation versus that of the current capsule formulation. Data derived from this study, in
addition to preclinical data and chemistry, manufacturing, and controls, will provide a basis
for dose selection in future studies.